Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011868 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 494
- Enrollment target
NCT01011868 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 494 participants.
The verdict
NCT01011868, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 494 participants
- Enrollment target
Study Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Interventions
- DRUG BI 10773 placebo
- DRUG BI 10773 low dose
- DRUG BI 10773 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011868
The ClinicalTrials.gov registry entry for NCT01011868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BI 10773 placebo is the first listed.
NCT01011868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011868 about?
NCT01011868 is a clinical study titled "Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes". The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
What is the current status of trial NCT01011868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 494 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01011868?
The interventions under investigation include: BI 10773 placebo (DRUG), BI 10773 low dose (DRUG), BI 10773 high dose (DRUG).
Who is sponsoring clinical trial NCT01011868?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.